FFO
ABEO icon

Fortitude Family Office’s Abeona Therapeutics ABEO Stock Holding History

Fortitude Family Office’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297 Buy
+48
New +$264 ﹤0.01% 2056

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fortitude Family Office's ABEO Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Abeona Therapeutics (ABEO) in Q2 2026: 48 shares worth $297. The stake represents ﹤0.01% of the portfolio and ranks #2056 among its holdings.

126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Fortitude Family Office held 48 shares of Abeona Therapeutics worth $297 as of Q2 2026.
  • Abeona Therapeutics was a new Fortitude Family Office position in Q2 2026.
  • Abeona Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2056 holding.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.